Specifically, by integrating Gleason scoring with other molecular characteristics of PCa, such as the expression of PlGF, VEGFR1, and PD-1, clinicians can better tailor treatment plans and improve outcomes for patients at risk of developing metastases. The gene discussed is FLT1; the disease is posterior cortical atrophy.